E Ococks1, A M Frankell1, N Masque Soler1, N Grehan1, A Northrop1, H Coles1, A M Redmond1, G Devonshire2, J M J Weaver1, C Hughes1, K Lehovsky1, A Blasko1, B Nutzinger1, R C Fitzgerald3, E Smyth4. 1. MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK. 2. Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK. 3. MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK. Electronic address: RCF29@MRC-CU.cam.ac.uk. 4. Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Electronic address: Elizabeth.Smyth@addenbrookes.nhs.uk.
Abstract
BACKGROUND: The incidence of esophageal adenocarcinoma (EAC) is rapidly rising and has a 5-year survival rate of <20%. Beyond TNM (tumor-node-metastasis) staging, no reliable risk stratification tools exist and no large-scale studies have profiled circulating tumor DNA (ctDNA) at relapse in EAC. Here we analyze the prognostic potential of ctDNA dynamics in EAC, taking into account clonal hematopoiesis with indeterminate potential (CHIP). PATIENTS AND METHODS: A total of 245 samples from 97 patients treated with neoadjuvant chemotherapy and surgery were identified from the prospective national UK Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) consortium data set. A pan-cancer ctDNA panel comprising 77 genes was used. Plasma and peripheral blood cell samples were sequenced to a mean depth of 7082× (range 2196-28 524) and ctDNA results correlated with survival. RESULTS: Characteristics of the 97 patients identified were as follows: 83/97 (86%) male, median age 68 years (SD 9.5 years), 100% cT3/T4, 75% cN+. EAC-specific drivers had higher variant allele fractions than passenger mutations. Using stringent quality criteria 16/79 (20%) were ctDNA positive following resection; recurrence was observed in 12/16 (75%) of these. As much as 78/97 (80%) had CHIP analyses that enabled filtering for CHIP variants, which were found in 18/78 (23%) of cases. When CHIP was excluded, 10/63 (16%) patients were ctDNA positive and 9/10 of these (90%) recurred. With correction for CHIP, median cancer-specific survival for ctDNA-positive patients was 10.0 months versus 29.9 months for ctDNA-negative patients (hazard ratio 5.55, 95% confidence interval 2.42-12.71; P = 0.0003). Similar outcomes were observed for disease-free survival. CONCLUSIONS: We demonstrate in a large, national, prospectively collected data set that ctDNA in plasma following surgery for EAC is prognostic for relapse. Inclusion of peripheral blood cell samples can reduce or eliminate false positives from CHIP. In future, post-operative ctDNA could be used to risk stratify patients into high- and low-risk groups for intensification or de-escalation of adjuvant chemotherapy.
BACKGROUND: The incidence of esophageal adenocarcinoma (EAC) is rapidly rising and has a 5-year survival rate of <20%. Beyond TNM (tumor-node-metastasis) staging, no reliable risk stratification tools exist and no large-scale studies have profiled circulating tumor DNA (ctDNA) at relapse in EAC. Here we analyze the prognostic potential of ctDNA dynamics in EAC, taking into account clonal hematopoiesis with indeterminate potential (CHIP). PATIENTS AND METHODS: A total of 245 samples from 97 patients treated with neoadjuvant chemotherapy and surgery were identified from the prospective national UK Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) consortium data set. A pan-cancer ctDNA panel comprising 77 genes was used. Plasma and peripheral blood cell samples were sequenced to a mean depth of 7082× (range 2196-28 524) and ctDNA results correlated with survival. RESULTS: Characteristics of the 97 patients identified were as follows: 83/97 (86%) male, median age 68 years (SD 9.5 years), 100% cT3/T4, 75% cN+. EAC-specific drivers had higher variant allele fractions than passenger mutations. Using stringent quality criteria 16/79 (20%) were ctDNA positive following resection; recurrence was observed in 12/16 (75%) of these. As much as 78/97 (80%) had CHIP analyses that enabled filtering for CHIP variants, which were found in 18/78 (23%) of cases. When CHIP was excluded, 10/63 (16%) patients were ctDNA positive and 9/10 of these (90%) recurred. With correction for CHIP, median cancer-specific survival for ctDNA-positive patients was 10.0 months versus 29.9 months for ctDNA-negative patients (hazard ratio 5.55, 95% confidence interval 2.42-12.71; P = 0.0003). Similar outcomes were observed for disease-free survival. CONCLUSIONS: We demonstrate in a large, national, prospectively collected data set that ctDNA in plasma following surgery for EAC is prognostic for relapse. Inclusion of peripheral blood cell samples can reduce or eliminate false positives from CHIP. In future, post-operative ctDNA could be used to risk stratify patients into high- and low-risk groups for intensification or de-escalation of adjuvant chemotherapy.
Authors: Carlos S Cabalag; Michael Yates; Mariana Benitez Corrales; Paul Yeh; Stephen Q Wong; Bonnie Z Zhang; Kenji M Fujihara; Lynn Chong; Michael W Hii; Sarah-Jane Dawson; Wayne A Phillips; Cuong P Duong; Nicholas J Clemons Journal: Ann Surg Date: 2021-08-20 Impact factor: 13.787
Authors: V F Bonazzi; L G Aoude; S Brosda; J M Lonie; K Patel; J J Bradford; L T Koufariotis; S Wood; B Mark Smithers; N Waddell; A P Barbour Journal: ESMO Open Date: 2022-03-23
Authors: Reetu Mukherji; Chao Yin; Rumaisa Hameed; Ali Z Alqahtani; Monika Kulasekaran; Aiwu R He; Benjamin A Weinberg; John L Marshall; Marion L Hartley; Marcus S Noel Journal: Biol Direct Date: 2022-06-06 Impact factor: 7.173
Authors: Susanne Flach; Karen Howarth; Sophie Hackinger; Christodoulos Pipinikas; Pete Ellis; Kirsten McLay; Giovanni Marsico; Tim Forshew; Christoph Walz; Christoph A Reichel; Olivier Gires; Martin Canis; Philipp Baumeister Journal: Br J Cancer Date: 2022-02-07 Impact factor: 9.075
Authors: Arlou Kristina Angeles; Petros Christopoulos; Zhao Yuan; Simone Bauer; Florian Janke; Simon John Ogrodnik; Martin Reck; Matthias Schlesner; Michael Meister; Marc A Schneider; Steffen Dietz; Albrecht Stenzinger; Michael Thomas; Holger Sültmann Journal: NPJ Precis Oncol Date: 2021-12-07